Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Post-transplant cyclophosphamide vs tacrolimus/methotrexate: Improved GRFS, reduced NRM, and less severe GVHD in myeloablative HLA-matched allogeneic transplantation

View Full Paper
Ask AI
Bookmark
Share

Authors

AMAlfonso MolinaQBQuenton R. BubbHHHitomi Hosoya

Discussion

Loading...

Member takes

Overview

Retrospective cohort study shows better GRFS and reduced GVHD in patients undergoing HCT with PTCy compared to TAC/MTX, implying PTCy as effective prophylaxis.

Key Points

  • Post-transplant cyclophosphamide resulted in improved GVHD-free-relapse-free survival compared to tacrolimus/methotrexate.
  • Patients receiving PTCy had a lower incidence of non-relapse mortality, indicating a clinically significant benefit.
  • Analysis used log-rank tests to compare survival outcomes across treatment groups during extensive follow-up.
  • Results suggest PTCy may enhance graft-versus-host disease prophylaxis, although there was a trend towards increased relapse rates in MRD positive patients.

Cite This Study

Molina et al. (2025) studied this question.

synapsesocial.com/papers/69362f7f4fa91c937236e527https://doi.org/10.1182/blood-2025-2494
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Post-transplant cyclophosphamide based GVHD prophylaxis in HLA-matched related and unrelated donor hematopoietic cell transplantation in adults with hematologic malignancies undergoing myeloablative conditioning: A CIBMTR analysis of 8,272 participants2025
  2. 2Safety and efficacy of post transplant cyclophosphamide vs tacrolimus plus methotrexate for gvhd prophylaxis in myelofibrosis2025
  3. 3Post-transplant cyclophosphamide (PTCy) versus other graft-versus-host disease prophylaxis strategies in reduced intensity allogeneic stem cell transplantation from related and matched unrelated donors in patients with acute myeloid leukemia and myelodysplastic syndromes: A study from the french society of bone marrow transplantation (SFGM-TC) registry2025
  4. 4Post-transplant cyclophosphamide improves survival compared to antithymocyte globulin in HLA-mismatched unrelated donor stem cell transplantation2025 · 1 citations
  5. 5Phase II Study of post transplant cyclophosphamide-based graft versus host disease prophylaxis after HLA-mismatched unrelated donor transplantation and reduced intensity conditioning: Results from the NMDP-sponsored access expansion Study2025